Fumaric acid esters in the management of psoriasis - PMC
网页2015年1月5日 · Fumaric acid esters (FAE) are small molecules with immunomodulating, anti-inflammatory, and anti-oxidative effects. FAE were introduced as a systemic psoriasis treatment in 1959 and empirically developed further between 1970 and 1990 in Germany, Switzerland, and the Netherlands. The development …
Psoriasis clinical guideline - American Academy of Dermatology
网页Among non-biologic systemic drugs, methotrexate is most commonly used for moderate to severe psoriasis with good efficacy and should be supplemented with folic acid. Cyclosporine is effective for moderate to severe pediatric psoriasis particularly for patients with pustular or erythrodermic psoriasis.
Long‐term real‐life safety profile and effectiveness of fumaric acid ...
网页2018年5月18日 · Fumaric acid esters (FAE s) are an established systemic treatment for moderate‐to‐severe psoriasis. However, the long‐term clinical safety and effectiveness of continuous FAE monotherapy and combination therapy have not been established.
Oral fumaric acid esters for psoriasis: abridged Cochrane …
网页2016年8月29日 · Fumaric acid esters (FAE s) are licensed for the treatment of moderate‐to‐severe psoriasis in Germany but are also used off‐label in many other countries. We conducted this systematic review to synthesize the highest‐quality evidence for the benefits and risks of FAE s for psoriasis.
Fumaric acid esters in the management of psoriasis
网页2015年1月5日 · Abstract. Fumaric acid esters (FAE) are small molecules with immunomodulating, anti-inflammatory, and anti-oxidative effects. FAE were introduced as a systemic psoriasis treatment in 1959 and empirically developed further between 1970 and 1990 in Germany, Switzerland, and the Netherlands.
Full article: Response to fumaric acid esters for plaque type psoriasis …
网页2022年6月28日 · Fumaric acid esters (FAEs) are a well-established treatment option for long-term therapy of moderate to severe plaque psoriasis. This study examines effectiveness of FAEs for the treatment of plaque psoriasis in real-world practice at 12 months and if patient characteristics affect the odds of clinical response.
Oral fumaric acid esters for the treatment of psoriasis
网页Oral fumaric acid esters (FAE) are licensed for the treatment of psoriasis in Germany but remain unlicensed in most other countries. This means that there are different treatment options offered to people in different countries. Review question. What is the available evidence for the benefits and risks of using FAE for treating psoriasis?
Fumaric acid esters in the management of psoriasis - PubMed
网页2015年1月5日 · Fumaric acid esters (FAE) are small molecules with immunomodulating, anti-inflammatory, and anti-oxidative effects. FAE were introduced as a systemic psoriasis treatment in 1959 and empirically developed further between 1970 and 1990 in Germany, Switzerland, and the Netherlands.
Oral fumaric acid esters for psoriasis - PubMed
网页2015年8月10日 · Several systemic therapies exist for moderate to severe psoriasis, including oral fumaric acid esters (FAE). These contain dimethyl fumarate (DMF), the main active ingredient, and monoethyl fumarate. FAE are licensed for psoriasis in Germany but used off-licence in many countries.
Fumaric acid esters for psoriasis: a systematic review
网页The findings suggest that FAEs are a safe and effective treatment option for the management of moderate to severe psoriasis in adult patients. Gastrointestinal side effects may occur on treatment initiation and may be minimised by slow dose titration.